Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-819 to Slow Progression of Multiple System Atrophy
NCT05695378Phase 2Terminated
- Sponsor
- Kainos Medicine, Inc.
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KM-819 in multiple system atrophy (MSA), sponsored by Kainos Medicine, Inc.. Started Feb 2023; status: terminated.
02
Drugs
KM-819
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05695378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695378.